Symbiosis launches multi-million pound sterile drug manufacturing capability

Published: 26-Sep-2012
Manufacturing Pharmaceutical

Receives MHRA licence to manufacture sterile liquid drugs in Stirling, Scotland


Symbiosis Pharmaceutical Services has been granted a licence by the MHRA, the UK government regulator, to manufacture sterile liquid, lyophilised, conventional, cytotoxic and biological drugs for biotechnology company clients around the world.

The Stirling, Scotland-based firm specialises in the small-scale contract manufacturing of sterile pharmaceuticals for clinical trials (fill/finish). Formed in 2011, Symbiosis has a team of 17 people and has successfully completed clinical trial manufacturing projects with clients in Europe and Asia, including Zealand Pharma and Encap Drug Delivery.

Colin MacKay, founder and chief executive of Symbiosis, says the firm built, qualified and licensed its new manufacturing facility within a matter of months.

‘Our intention is to be both the fastest, and the best, small-scale sterile fill/finish company in the world,’ he says.

The new Symbiosis manufacturing facility includes two manufacturing suites, one of which is capable of handling cytotoxic and highly potent pharmaceuticals, built with integrated Restricted Access Barrier System (RABS) technology.

While Symbiosis specialises in phase I and phase II GMP manufacture of liquid, lyophilised, conventional, cytotoxic and biological drugs, it also provides a range of closely associated services, including analytical testing, clinical labelling and packaging, Qualified Person release and controlled temperature storage and shipment.

  • Companies:
  • Symbiosis Pharmaceutical
See more

You may also like

Finance

Symbiosis acquires a 20,000 sq/ft building financed by Barclays Corporate Bank

Read more
Symbiosis acquires a 20,000 sq/ft building in Stirling, UK, to house new high-tech medicines manufacturing capacity, financed by £1.2m from Barclays Corporate Bank PLC

Trending Articles

  1. Drive for innovation: New biologicals development centre of Boehringer Ingelheim Boehringer Ingelheim, a leading research-driven biopharmaceutical company, is dedicated to advancing innovation in areas with significant medical needs. With its primary research and development centre based in Biberach, the company employs approximately 7,500 individuals who are focused on creating human pharma, as well as animal health products
  2. UPDATE: US Pharmacopeia makes comments public on endotoxin testing overhaul The USP has published the comments the organisation received in response to the addition of non-animal derived endotoxin testing methods, as well as an FAQ page on the issue
  3. BES completes Terumo Aortic cleanroom build started pre-covid Cleanroom construction expert has finished the 2,400 sqm manufacturing facility with cGMP cleanrooms for the medical device manufacturer
  4. FDA Warning Letter: ImprimisRx facility features stained HEPA filters Following a 2022 inspection, ophthalmic medicine production expert ImprimisRx received a 483 form. A year later a warning letter has been sent emphasising major issues with the facility design and operation
  5. The importance of growth promotion testing Given the critical nature of microbiological quality tests which are employed to ensure that pharmaceutical products are safe for human use, it is in turn essential to undertake quality control (QC) tests to ensure that the culture media being used for these is fit for purpose and performs properly. Cherwell Laboratories' Steven Brimble explains

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Finance

Symbiosis acquires a 20,000 sq/ft building financed by Barclays Corporate Bank

Symbiosis acquires a 20,000 sq/ft building in Stirling, UK, to house new high-tech medicines manufacturing capacity, financed by £1.2m from Barclays Corporate Bank PLC
Finance

Symbiosis Pharmaceutical Services raises $1.25m

Scotland-based sterile manufacturing services provider has received finance from Allied Irish Bank (GB) to support its 2020 growth strategy
Design & Build

Symbiosis invests $1.9m in UK sterile biologics facility expansion

UK-based CMO has expanded its Scottish facility driven by the market growth of ATMPs such as viral vector and other biopharmaceuticals
Manufacturing

Symbiosis secures FDA viral vector process approval

The Scottish CDMO has received the go-ahead for aseptic manufacturing of viral vector products for commercial supply into the US market
Design & Build

Drive for innovation: New biologicals development centre of Boehringer Ingelheim

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, is dedicated to advancing innovation in areas with significant medical needs. With its primary research and development centre based in Biberach, the company employs approximately 7,500 individuals who are focused on creating human pharma, as well as animal health products
Design & Build

BES completes Terumo Aortic cleanroom build started pre-covid

Cleanroom construction expert has finished the 2,400 sqm manufacturing facility with cGMP cleanrooms for the medical device manufacturer
Regulatory

UPDATE: US Pharmacopeia makes comments public on endotoxin testing overhaul

The USP has published the comments the organisation received in response to the addition of non-animal derived endotoxin testing methods, as well as an FAQ page on the issue
Subscribe now